NEWS
山东四环药业股份有限公司创新药物高端生产制造基地项目环境影响评价第二次信息公示- Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-r
The European Commission has granted marketing authorisation in the European Union (EU) for Nubeqa® (darolutamide), an oral androgen receptor inhibitor (ARi). The approval is based on Phase III ARAMIS
- Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some
- China smacks 48 officials, including ex-FDA official, in Changsheng vaccine scandal
China’s anticorruption authorities have punished 48 officials found responsible for the Changchun Changsheng Life Sciences vaccine scandal that provoked public outrage last summer.
- EU expands look at Zhejiang Huahai as impurities show up in other 'sartans'
A global recall may get expanded beyond valsartan as regulators continue to find potentially cancer-causing impurities in other “sartan” products.
- India watching China’s measures to ease drug-import norms
In June, pharmaceutical exporters from India had meetings with representatives from the China Food & Drugs Administration (CFDA) on the problems being faced by them in the Chinese market.